Cancer Genetics, Inc. said thursday that it has priced its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share, which is at the low end of it previous expected range of $10.00 to $12.00 per share.
The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6 million, assuming no exercise of the over-allotment option, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Cancer Genetics has granted the representative of the underwriters a 45-day option to purchase up to 90,000 additional shares of common stock from the company to cover over-allotments, if any.
Shares of Cancer Genetics' common stock are expected to be quoted on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol "CGIX" beginning on April 5, 2013.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.